Related Experiment Video
Updated: May 6, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.5K
Biological therapies in rheumatic diseases
F Conti1, F Ceccarelli, L Massaro
1Department of Internal Medicine and Medical Specialties, Rheumatology, 'Sapienza' University, Rome, Italy.
La Clinica Terapeutica
|November 13, 2013
Summary
Biological drugs offer revolutionary treatment for chronic inflammatory rheumatic diseases, especially for patients unresponsive to standard therapies. This review details their targeted mechanisms, efficacy, and safety for conditions like rheumatoid arthritis.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Chronic inflammatory rheumatic diseases pose significant challenges, particularly for patients resistant to conventional treatments.
- Biological drugs represent a paradigm shift in managing these conditions.
Purpose of the Study:
- To provide a comprehensive overview of currently available biological drugs for rheumatic diseases.
- To analyze their mechanisms of action, therapeutic indications, efficacy, and adverse events.
Main Methods:
- Review of existing literature on biological therapies for rheumatic diseases.
- Analysis of drug mechanisms targeting pro-inflammatory cytokines, CTLA-4, and B cell pathways.
- Evaluation of clinical data on efficacy and safety profiles.
Main Results:
- Biological drugs have revolutionized treatment, offering improved prognoses and clinical remission in diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus.
- Targeted inhibition of specific molecular pathways (e.g., TNF, IL-1, IL-6, CTLA-4) is key to their efficacy.
- Data on therapeutic indications, efficacy, and adverse events for various biological agents are presented.
Conclusions:
- Biological drugs are effective in treating chronic inflammatory rheumatic diseases, especially in treatment-resistant cases.
- Understanding their specific mechanisms and safety profiles is crucial for optimal patient management.
- These therapies have significantly improved outcomes for patients with several debilitating rheumatic conditions.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
01:21Rheumatic Heart Disease III: Medical Management
548
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
548
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
01:29Microorganisms in Medicine and Therapeutics
1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K